Bayer commissions $3 million water plant at Manukau site
High quality water for basis of animal medicines // Up to 2000 litres each of Water For Injection and Pure Water per hour // More investment planned for future
Auckland, 4 November, 2016 – Bayer is continuing its investment in producing high-quality animal health medicines in New Zealand with the commissioning today (Friday 4 November 2016) of a new $3 million water treatment station at its Manukau production site.
The new plant takes ordinary tap water and through a system of filtering, deionizing and softening converts it into Pure Water (PW). It is then further refined and distilled to create Water For Injection (WFI).
Both types of water are used in manufacturing a wide range of animal medicines and products ranging from metabolics for dairy cows to drenches and supplements for farm livestock and horses.
Bayer New Zealand managing director Derek Bartlett says the new water treatment plant is a major leap for the production site.
“Previously it would take about six hours to produce 2000 litres of Water For Injection. Now we can produce 2000 litres in one hour. We can now get high quality water whenever we want without any restrictions, which will impact positively on our production times.”
Another important feature of the water treatment plant is its ability to self-monitor.
“Basically, it self-checks itself to ensure the water being produced does not get contaminated or go out of spec,” says Bartlett.
As well as treating water, the new plant also distributes it throughout the Manukau production site 24/7 and has two large storage tanks.
Following the commissioning of the plant, there will be a two month testing and validation process before full manufacturing begins in January.
The new water treatment plant is part of a series of multi-million upgrades to the Manukau plant.
Other improvements will be made to its Liquids and Pastes production facility starting next year.
“Bayer firmly believes in supporting our local farming industry here in New Zealand,” says Bartlett.
“To do that, it is crucial that we invest in our manufacturing plant, which not only produces animal medicines for local use, but also exports to more than 70 countries around the world.”
William Malpass, phone 021 935 217
Bayer: Science For A Better Life
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2015, the Group employed around 117,000 people and had sales of EUR 46.3 billion. Capital expenditures amounted to EUR 2.6 billion, R&D expenses to EUR 4.3 billion. These figures include those for the high-tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015. For more information, go to www.bayer.com.
This news release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.